Skip to main content
SpringerLink
Log in

Kritischer Überblick zu Outcome-Parametern bei Patienten mit primärem Sjögren-Syndrom

Critical overview of outcome parameters for patients with primary Sjögren’s syndrome

  • Leitthema
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

Zusammenfassung

Insbesondere für klinische Studien, aber auch für den Praxisalltag, sind Parameter oder Messinstrumente erforderlich, anhand derer der unmittelbare Behandlungserfolg, die Krankheitsaktivität und ggf. auch der weitere Krankheitsverlauf einer Erkrankung beurteilt werden können, so genannte „Outcome“-Parameter. Solche Kriterien können auch helfen, Risikogruppen von Patienten zu definieren, die einer besonderen Kontrolle bzw. Therapie bedürfen. Sie sollten möglichst zuverlässig, objektiv und valide sein, z. B. um eine gute Vergleichbarkeit von Studienergebnissen zu gewährleisten. Outcome-Parameter sind daher gezielt für das jeweilige Krankheitsbild bzw. die jeweilige Fragestellung zu entwickeln und/oder neu zu validieren. Für das Sjögren-Syndrom, eine häufige, systemische Autoimmunerkrankung unklarer Genese, existieren bislang nur begrenzte therapeutische Möglichkeiten. Vor dem Hintergrund zu erwartender neuer Therapieansätze gibt der vorliegende Artikel einen kritischen Überblick über die verfügbaren bzw. in Entwicklung befindlichen möglichen Outcome-Parameter für Sjögren-Patienten.

Abstract

Not only in the context of clinical trials in particular, but also in daily clinical practice, outcome parameters or measuring instruments are essential to assess the efficacy of a therapeutic intervention, its influence on disease activity and potentially also to predict further disease course. Such criteria can assist in the identification of patient risk groups that may require special checkups or interventions. Moreover, these parameters should be reliable, objective and valid, e.g. to allow comparison of results from different studies. Therefore, outcome parameters need to be developed and/or validated in a targeted manner for individual diseases or investigations. To date, we have only limited therapeutic options for Sjögren’s syndrome, a frequent systemic autoimmune disorder of unknown origin. Against the background of the new therapy approaches expected, this article provides a critical overview of available and newly developed outcome parameters for patients with Sjögren’s syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Bowman SJ, Hamburger J, Richards A et al (2009) Patient-reported outcomes in primary Sjögren’s syndrome: comparison of the long and short versions of the Profile of Fatigue and Discomfort-Sicca Symptoms Inventory. Rheumatology (Oxford) 48(2):140–143

    Google Scholar 

  2. Chikui T, Okamura K, Tokumori S et al (2006) Quantitative analyses of sonographic images of the parotid gland in patients with Sjögren’s syndrome. Ultrasound Med Biol 32(5):617–622

    Article  PubMed  Google Scholar 

  3. Chisholm DM, Mason DK (1968) Labial salivary gland biopsy in Sjögren’s disease. J Clin Pathol 21(5):656–660

    Article  CAS  PubMed  Google Scholar 

  4. Dankof A, Morawietz L, Feist E (2006) Labial salivary gland biopsy in Sjögren’s syndrome. Pathologe 27(6):416–421

    Article  CAS  PubMed  Google Scholar 

  5. Feist E, Dorner T, Hansen A (2007) Indications and options of new immune modulatory therapies for Sjögren’s syndrome. Z Rheumatol 66(8):679–685

    Article  CAS  PubMed  Google Scholar 

  6. Feist E, Hermann KG, Dankof A (2009) Vasculopathy in Sjögren’s syndrome. Z Rheumatol 68(4):305–311

    Article  CAS  PubMed  Google Scholar 

  7. Fox PC, Bowman SJ, Segal B et al (2008) Oral involvement in primary Sjögren syndrome. J Am Dent Assoc 139(12):1592–1601

    PubMed  Google Scholar 

  8. Gritzmann N, Rettenbacher T, Hollerweger A et al (2003) Sonography of the salivary glands. Eur Radiol 13(5):964–975

    CAS  PubMed  Google Scholar 

  9. Groom J, Kalled SL, Cutler AH et al (2002) Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren’s syndrome. J Clin Invest 109(1):59–68

    CAS  PubMed  Google Scholar 

  10. Hansen A, Lipsky PE, Dörner T (2007) B-cell lymphoproliferation in chronic inflammatory rheumatic diseases. Nat Clin Pract Rheumatol 3(10):561–569

    Article  CAS  PubMed  Google Scholar 

  11. Hansen A, Lipsky PE, Dörner T (2007) B cells in Sjögren’s syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue. Arthritis Res Ther 9(4):218

    Article  PubMed  Google Scholar 

  12. Hocevar A, Rainer S, Rozman B et al (2007) Ultrasonographic changes of major salivary glands in primary Sjögren’s syndrome. Evaluation of a novel scoring system. Eur J Radiol 63(3):379–383

    Article  PubMed  Google Scholar 

  13. Ioannidis JP, Vassiliou VA, Moutsopoulos HM (2002) Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren’s syndrome. Arthritis Rheum 46(3):741–747

    Article  PubMed  Google Scholar 

  14. Kassan SS, Moutsopoulos HM (2004) Clinical manifestations and early diagnosis of Sjögren syndrome. Arch Intern Med 164(12):1275–1284

    Article  PubMed  Google Scholar 

  15. Pijpe J, van Imhoff GW, Spijkervet FK et al (2005) Rituximab treatment in patients with primary Sjögren’s syndrome: an open-label phase II study. Arthritis Rheum 52(9):2740–2750

    Article  CAS  PubMed  Google Scholar 

  16. Pijpe J, van Imhoff GW, Vissink A et al (2005) Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjögren’s syndrome and associated MALT lymphoma. Ann Rheum Dis 64(6):958–960

    Article  CAS  PubMed  Google Scholar 

  17. Pillemer SR, Smith J, Fox PC et al (2005) Outcome measures for Sjögren’s syndrome, April 10–11, 2003, Bethesda, Maryland, USA. J Rheumatol 32(1):143–149

    PubMed  Google Scholar 

  18. Seror R, Ravaud P, Bowman S et al (2009) EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI): Development of a consensus systemic disease activity index in primary Sjogren’s syndrome. Ann Rheum Dis

  19. Shimizu M, Okamura K, Yoshiura K et al (2006) Sonographic diagnostic criteria for screening Sjögren’s syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102(1):85–93

    Article  PubMed  Google Scholar 

  20. Theander E, Henriksson G, Ljungberg O et al (2006) Lymphoma and other malignancies in primary Sjögren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 65(6):796–803

    Article  CAS  PubMed  Google Scholar 

  21. Thomson WM, Chalmers JM, Spencer AJ et al (1999) The Xerostomia Inventory: a multi-item approach to measuring dry mouth. Community Dent Health 16(1):12–17

    CAS  PubMed  Google Scholar 

  22. Tzioufas AG, Boumba DS, Skopouli FN et al (1996) Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren’s syndrome. Arthritis Rheum 39(5):767–772

    Article  CAS  PubMed  Google Scholar 

  23. Vitale S, Goodman LA, Reed GF et al (2004) Comparison of the NEI-VFQ and OSDI questionnaires in patients with Sjogren’s syndrome-related dry eye. Health Qual Life Outcomes 2:44

    Article  PubMed  Google Scholar 

  24. Vitali C, Bombardieri S, Jonsson R et al (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61(6):554–558

    Article  CAS  PubMed  Google Scholar 

  25. Wernicke D, Hess H, Gromnica-Ihle E et al (2008) Ultrasonography of salivary glands – a highly specific imaging procedure for diagnosis of Sjögren’s syndrome. J Rheumatol 35(2):285–293

    PubMed  Google Scholar 

  26. Zintzaras E, Voulgarelis M, Moutsopoulos HM et al (2005) The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165(20):2337–2344

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehung hin: E. Feist hat Vortragshonorare durch die Fa. Roche Pharma AG Deutschland erhalten.

Author information

Authors and Affiliations

  1. Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité-Universitätsmedizin Berlin, Campus Mitte, Berlin, Deutschland

    E. Feist

  2. Park-Klinik Weißensee, Akademisches Lehrkrankenhaus der Charité, Schönstr. 80, 13086, Berlin, Deutschland

    A. Hansen

Authors
  1. E. Feist
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Hansen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Feist, E., Hansen, A. Kritischer Überblick zu Outcome-Parametern bei Patienten mit primärem Sjögren-Syndrom. Z. Rheumatol. 69, 25–31 (2010). https://doi.org/10.1007/s00393-009-0516-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-009-0516-5

Schlüsselwörter

Keywords

Search

Navigation